Media Release
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Leading the first clinical approval of an in vivo gene editing drug mediated by LNP in China
Share
LATESTNEWS
-
CDE Clears IND Application for Therapeutic Candidate Targeting ATTR
Mar 18, 2024
-
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Mar 13, 2024
-
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
Feb 15, 2024
